INTRODUCTION
Tuberculosis (TB) is a public problem. The 1990's have witnessed a resurgence of TB. Reemergent TB is fuelled by the pandemic HIV and AIDS and by single and multi drug resistance. 1 Treatment with anti-tubercular drugs is the only effective method to cure active TB disease. Highly effective medications for tuberculosis have been available for nearly 50 years. Bactericidal anti-tuberculosis drugs like, rifampicin, isoniazid, pyrazinamide, streptomycin and bacteriostatic like, ethambutol, ethionamide, thiacetozone, paraaminosalicylic acid and cycloserine are in practice. 2 Drug susceptibility testing is designed to show that the great majority of bacilli in culture are as susceptible to a given drug as one or more known susceptible strains. It is also of value in the surveillance of tuberculosis in order to detect and monitor emergence of drug resistance.
There has, however, been considerable debate whether a susceptibility test is essential for the management of individual patients or not. In some countries, a fear of litigation leads to a regular use of susceptibility testing and it is highly desirable in regions where drug and multi-drug resistant is common. 3 TB drug resistance is a major problem that threatens the success of DOTS. WHO has recommended treatment strategy for detection and cure of TB as well as global tuberculosis control. Drug resistance arises due to the improper use of drugs in the treatment of TB patients. This improper use is a result of a number of actions, including administration of improper treatment regimens by health care providers and failure to ensure the completion of whole course of treatment. Essentially, drug-resistance arises in areas with poor TB control program.
Unfortunately, owing to poor prescribing practices, inadequately formulated drugs, intermittent supplies of drugs, poor compliance and a lack of supervision of therapy, drug resistance is a serious and increasing problem in many regions. 4 The objective of the study is to determine the first line anti-tubercular resistance in patients visiting German Nepal Tuberculosis Project.
MATERIALS AND METHODS
This study was conducted in German-Nepal Tuberculosis Project (GENETUP) Kalimati, Kathmandu, Nepal from October 28, 2007 to September 01, 2008. This work is the continuation study of Regmi S., et al, 2008. 5 Anti-tubercular drug susceptibility test was performed using proportion method.
For the proportion method, a suspension of bacteria equivalent to McFarland No. 1 was made. To a sterile glass tube containing glass beads, few drops of normal saline was added. About 1mg of colonies was transferred to the glass tube with sterile loop from the culture tube. The colonies were homogenized by placing the tube in vertex (rotator). After complete homogenization, the suspension was made as McFarland std. 1 by adding normal saline. The standard suspension was diluted as 10 -1 , 10 -2 and 10 -3 . The dilution 10 -1 was taken as test solution and 10 -3 was used for control. For anti-tuberculosis drug susceptibility test, LJ media with different drug in different concentration was used. The concentration of INH, EMB, SM and RMP in LJ medium was (0.025, 0.05, 0.1 and 0.2 µg/ml), (0.125, 0.25, 0.5 and 2 µg/ml), (0.5, 1, 2, and 4 µg/ml) and (2.5, 5, 10 and 40 µg/ml) respectively in 4 tube sets. The incubation and reading and interpretation was done as per the standards for LJ proportion method. Quality control was done by maintaining strict aseptic condition during handling and processing of the bacilli. The sterility of each batch of test medium was confirmed by incubating 5% un-inoculated tubes with the inoculated tubes as control.
RESLUTS
Among the 141 M. tuberculosis isolates, 19 (13.4%) were resistant to INH, 11 (7.8%) were resistant to EMB, 24 (17.1%) were resistant to SM and 17 (12.1%) were resistant to RMP. Among the 4 drugs, EMB was most sensitive (n=130, 92.2%) followed by RMP (n=124, 87.9%), INH (n=122, 86.5%). Among 4 drugs, SM appeared to be least sensitive of all drugs. The resistant to all 4 drugs were 8 isolates, any 3 drugs were 4 isolates, any 2 drugs were 10 isolates and any one of the drugs were 31 isolates. The multi-drugs resistant isolates were 12 (8.5%). Proportion of drug resistant three drugs (6.3%) and four drugs was 5.6%.
DISCUSSION
Drug-resistant TB is a serious public health issue in many developing countries, as its treatment is longer and requires more expensive drugs. 6 Recurrence of TB cases should be treated only after performing antibiotics sensitivity tests. 7 Drug resistance reports available from Nepal have shown the emergence of multi-drug resistance (MDR). In Nepal, acquired resistance to one or more drugs arising during the course of treatment is around 65% to isonizid and around 30% to rifampicin. 8 Initial drug resistance in Nepal has been reported to be 5-24%. 9 Shrestha et al. (1996) reported the initial resistance for each specific drug as RMP in 4.5%, INH in 9.4%, SM in 18.3% and EMB in 7.3% and RMP+INH in 3.6% in a study carried out for 8 years at Urban TB clinic in Kathmandu valley. 9 In our study, resistant to individual drug like, isonizid was 13.5%, ethambutol was 7.8%, streptomycin was 17.1% and rifampicin was 12.1%. Combined INH+RMP resistance was 8.5%. In our study, drug resistant to one drug was found to be 12.6%, 2 drugs was 7.6%, 3 drugs was 6.3% and to 4 drugs 5.6% and Int J Infect Microbiol 2013;2(2):45-48 
CONCLUSION
The drug resistance is emerging in Nepal including the rise of MDR TB. National Tuberculosis control program should ensure that the defaulters in DOTS are reduced and prevent emergence of MDR TB. The program should also monitor the first line drug resistance continuously.
